REG - Syncona Limited - Result of AGM

SynconaAnnouncement

01/08/2023 15:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230801:nRSA9553Ha&default-theme=true

RNS Number : 9553H  Syncona Limited  01 August 2023

Syncona Limited

Result of Annual General Meeting

1 August 2023

At the Annual General Meeting of Syncona Limited (the "Company") held today,
all Resolutions as set out in the 'Notice of the 2023 Annual General Meeting'
dated 28 June 2023 sent to shareholders of the Company (the "Notice") were
duly passed.

Resolutions 1 to 13 were proposed as Ordinary Resolutions. Resolution 14 was
proposed as a Special Resolution and Resolution 15 was proposed as an
Extraordinary Resolution.

Details of the proxy voting results, which should be read alongside the
Notice, are noted below:

 No  Resolution                                                                     For          Discretion  Against        Abstain (withheld)
 1   Receive and consider the Annual Audited Financial Statements of the Company    509,248,042  (0)         9,810 (0.01%)  3,726
     for the year ended 31 March 2023, together with the Reports of the Directors

     and Auditors therein                                                           (99.99%)     (0%)
 2   Re-appointment of Deloitte LLP (Guernsey Branch) as Auditors                   499,812,823  (0)         64,344         9,384,411

                                                                                    (99.99%)     (0%)        (0.01%)
 3   Authorise the Directors to determine the remuneration of the Auditors          499,860,699  (0)         16,468         9,384,411

                                                                                    (99.99%)     (0%)        (0.01%)
 4   Re-elect Melanie Gee as a Director                                             506,670,977  (0)         2,586,875      3,726

                                                                                    (99.49%)     (0%)        (0.51%)
 5   Re-elect Julie Cherrington as a Director                                       509,234,482  (0)         23,370         3,726

                                                                                    (99.99%)     (0%)        (0.01%)
 6   Re-elect Cristina Csimma as a Director                                         509,234,482  (0)         23,370         3,726

                                                                                    (99.99%)     (0%)        (0.01%)
 7   Re-elect Virginia Holmes as a Director                                         506,670,977  (0)         2,586,875      3,726

                                                                                    (99.49%)     (0%)        (0.51%)
 8   Re-elect Robert Hutchinson as a Director                                       506,636,608  (0)         2,616,589      8,381

                                                                                    (99.49%)     (0%)        (0.51%)
 9   Re-elect Kemal Malik as a Director                                             506,636,608  (0)         2,616,589      8,381

                                                                                    (99.49%)     (0%)        (0.51%)
 10  Re-elect Gian Piero Reverberi as a Director                                    506,636,608  (0)         2,616,589      8,381

                                                                                    (99.49%)     (0%)        (0.51%)

 11  Approve the report on implementation of the Remuneration Policy for         509,148,250  211,077   93,843     14,961
     Non-Executive Directors

                                                                                 (99.94%)     (0.04%)   (0.02%)
 12  Approve the Company's Remuneration Policy                                   509,149,180  (0)       101,934    10,464

                                                                                 (99.98%)     (0%)      (0.02%)
 13  Authority to allot and issue shares, as set out in the Notice               508,406,358  (0)       848,009    7,211

                                                                                 (99.83%)     (0%)      (0.17%)
 14  Authorise the Company to purchase its own shares, as set out in the Notice  507,133,706  (0)       2,124,146  3,726

                                                                                 (99.58%)     (0%)      (0.42%)
 15  Disapply pre-emption rights, as set out in the Notice                       487,907,670  (0)       8,081,414  13,272,494

                                                                                 (98.37%)     (0%)      (1.63%)

A vote withheld is not a vote in law and has not been counted in the votes for
and against a resolution.

In accordance with the Listing Rule 9.6.2, a copy of all the resolutions
passed other than resolutions concerning ordinary business have been submitted
to the Financial Conduct Authority via the National Storage Mechanism and will
shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

The full text of the resolutions can be found in the Notice, which is
available on the Company's website at
https://www.synconaltd.com/investors/shareholder-information/shareholder-documents/
(https://www.synconaltd.com/investors/shareholder-information/shareholder-documents/)
.

Enquiries

Syncona Limited

Annabel Clark / Fergus Witt

Tel: +44 (0) 20 3981 7940

 

FTI Consulting

Ben Atwell / Natalie Garland-Collins / Tim Stamper

Tel: +44 (0) 20 3727 1000

 

About Syncona:

Syncona's purpose is to invest to extend and enhance human life. We do this by
creating and building companies to deliver transformational treatments to
patients in areas of high unmet need.

 

Our strategy is to create, build and scale companies around exceptional
science to create a diversified portfolio of 20-25 globally leading life
science businesses, across development stage, modality and therapeutic areas,
for the benefit of all our stakeholders. We focus on developing treatments for
patients by working in close partnership with world-class academic founders
and management teams. Our balance sheet underpins our strategy enabling us to
take a long-term view as we look to improve the lives of patients with no or
poor treatment options, build sustainable life science companies and deliver
strong risk-adjusted returns to shareholders.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGUPUMURUPWGCG